File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma

TitleTargeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma
Authors
Issue Date2011
Citation
Future Oncology, 2011, v. 7 n. 10, p. 1149-1167 How to Cite?
AbstractDespite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy. © 2011 Future Medicine Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/194330
ISSN
2015 Impact Factor: 2.129
2015 SCImago Journal Rankings: 0.957
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorZhou, Q-
dc.contributor.authorLui, VWY-
dc.contributor.authorYeo, W-
dc.date.accessioned2014-01-30T03:32:27Z-
dc.date.available2014-01-30T03:32:27Z-
dc.date.issued2011-
dc.identifier.citationFuture Oncology, 2011, v. 7 n. 10, p. 1149-1167-
dc.identifier.issn1479-6694-
dc.identifier.urihttp://hdl.handle.net/10722/194330-
dc.description.abstractDespite recent advances in the understanding of the biologic basis of hepatocellular carcinoma (HCC) development, the clinical management of the disease remains a major challenge. Deregulation of the PI3K/Akt/mTOR pathway, which is a prototypic survival pathway, is increasingly implicated in HCC carcinogenesis. In this article, we detailed the role of this pathway in the pathogenesis of HCC and provide an update on the preclinical and clinical development of various agents targeting this key survival/proliferation pathway, which include various PI3K inhibitors, Akt inhibitors and mTOR inhibitors for HCC. In addition, we highlighted the therapeutic potential of combination strategy for mTOR inhibitors with conventional chemotherapy, in particular, antimicrotubule agents, other molecular targeting agents, as well as radiotherapy. © 2011 Future Medicine Ltd.-
dc.languageeng-
dc.relation.ispartofFuture Oncology-
dc.titleTargeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.2217/fon.11.95-
dc.identifier.pmid21992728-
dc.identifier.scopuseid_2-s2.0-80054113770-
dc.identifier.volume7-
dc.identifier.issue10-
dc.identifier.spage1149-
dc.identifier.epage1167-
dc.identifier.isiWOS:000297101200009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats